TGFB1 and central nervous system cancer: An additional target of immunotherapy could be TAMs, which are recruited to the glioma TME and release anti-inflammatory cytokines, such as transforming growth factor β (TGF-β) and IL-10, and pro-inflammatory cytokines including TNF-α, IL1-β and CXCL10 (28, 102).